|
2
|
12
|
3okiB |
Crystal structure of human fxr in complex with (2s)-2-[2-(4-chlorophenyl)-1h-benzimidazol-1-yl]-n,2-dicyclohexylethanamide |
|
3
|
10
|
3okhB |
Crystal structure of human fxr in complex with 2-(4-chlorophenyl)-1-[(1s)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1h-benzimidazole-6-carboxylic acid |
|
86
|
230
|
3olfA |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid |
|
3
|
11
|
3olfB |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid |
|
3
|
12
|
3omkB |
Crystal structure of human fxr in complex with (2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexyl-n-(2-methylphenyl)ethanamide |
|
86
|
230
|
3ommA |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid |
|
3
|
13
|
3ommB |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid |
|
87
|
230
|
3omkA |
Crystal structure of human fxr in complex with (2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexyl-n-(2-methylphenyl)ethanamide |
|
51
|
186
|
3ojiA |
X-ray crystal structure of the py13 -pyrabactin complex |
|
84
|
230
|
3okiA |
Crystal structure of human fxr in complex with (2s)-2-[2-(4-chlorophenyl)-1h-benzimidazol-1-yl]-n,2-dicyclohexylethanamide |
|
88
|
228
|
3okhA |
Crystal structure of human fxr in complex with 2-(4-chlorophenyl)-1-[(1s)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1h-benzimidazole-6-carboxylic acid |
|
3
|
12
|
3oofB |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid |
|
3
|
12
|
3ookB |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3,5-difluorobenzoic acid |
|
93
|
230
|
3oofA |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid |
|
51
|
181
|
3nr4A |
Pyrabactin-bound pyl2 |
|
48
|
175
|
3njoA |
X-ray crystal structure of the pyr1-pyrabactin a complex |
|
50
|
182
|
3nj1A |
X-ray crystal structure of the pyl2(v114i)-pyrabactin a complex |
|
46
|
178
|
3nj0A |
X-ray crystal structure of the pyl2-pyrabactin a complex |
|
50
|
181
|
3ns2A |
High-resolution structure of pyrabactin-bound pyl2 |
|
2
|
10
|
3mnoB |
Crystal structure of the agonist form of mouse glucocorticoid receptor stabilized by (a611v, f608s) mutations at 1.55a |
|
103
|
258
|
3mnoA |
Crystal structure of the agonist form of mouse glucocorticoid receptor stabilized by (a611v, f608s) mutations at 1.55a |
|
100
|
257
|
3mnpA |
Crystal structure of the agonist form of mouse glucocorticoid receptor stabilized by (a611v, v708a, e711g) mutations at 1.50a |
|
100
|
258
|
3mneA |
Crystal structure of the agonist form of mouse glucocorticoid receptor stabilized by f608s mutation at 1.96a |
|
2
|
10
|
3mnpB |
Crystal structure of the agonist form of mouse glucocorticoid receptor stabilized by (a611v, v708a, e711g) mutations at 1.50a |
|
2
|
10
|
3mneB |
Crystal structure of the agonist form of mouse glucocorticoid receptor stabilized by f608s mutation at 1.96a |
|
49
|
181
|
3kdiA |
Structure of (+)-aba bound pyl2 |
|
41
|
177
|
3kl1A |
Crystal structure of abscisic acid receptor pyl2 at 1.55 a |
|
107
|
270
|
3kduA |
Crystal structure of peroxisome proliferator-activatedeceptor alpha (pparalpha) complex with n-3-((2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl)methoxy)benzyl)-n-((4-methylphenoxy)carbonyl)glycine |
|
46
|
185
|
3klxA |
Crystal structure of native abscisic acid receptor pyl3 |
|
99
|
270
|
3kdtA |
Crystal structure of peroxisome proliferator-activatedeceptor alpha (pparalpha) complex with n-3-((2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl)methoxy)benzyl)-n-(methoxycarbonyl)glycine |
|
53
|
189
|
3kdhA |
Structure of ligand-free pyl2 |
|
80
|
239
|
3k6pA |
Estrogen related receptor alpha in complex with an ether based ligand |
|
51
|
179
|
3jrsA |
Crystal structure of (+)-aba-bound pyl1 |
|
85
|
251
|
3h52A |
Crystal structure of the antagonist form of human glucocorticoid receptor |
|
2
|
10
|
3h52M |
Crystal structure of the antagonist form of human glucocorticoid receptor |
|
2
|
13
|
3fxvB |
Identification of an n-oxide pyridine gw4064 analogue as a potent fxr agonist |
|
94
|
229
|
3fxvA |
Identification of an n-oxide pyridine gw4064 analogue as a potent fxr agonist |
|
101
|
253
|
3az3A |
Crystal structure analysis of vitamin d receptor |
|
96
|
253
|
3az2A |
Crystal structure analysis of vitamin d receptor |
|
99
|
253
|
3az1A |
Crystal structure analysis of vitamin d receptor |
|
122
|
338
|
2zshA |
Structural basis of gibberellin(ga3)-induced della recognition by the gibberellin receptor |
|
20
|
67
|
2zsiB |
Structural basis of gibberellin(ga4)-induced della recognition by the gibberellin receptor |
|
20
|
66
|
2zshB |
Structural basis of gibberellin(ga3)-induced della recognition by the gibberellin receptor |
|
119
|
339
|
2zsiA |
Structural basis of gibberellin(ga4)-induced della recognition by the gibberellin receptor |
|
100
|
250
|
2yloA |
Targeting the binding function 3 site of the androgen receptor through in silico molecular modeling |
|
93
|
249
|
2ylpA |
Targeting the binding function 3 site of the androgen receptor through in silico molecular modeling |
|
95
|
249
|
2ylqA |
Targeting the binding function 3 site of the androgen receptor through in silico molecular modeling |
|
80
|
233
|
2qw4A |
Human nr4a1 ligand-binding domain |
|
94
|
268
|
2q8sA |
X-ray crystal structure of the nuclear hormone receptor ppar-gamma in a complex with a ppar gamma/alpha dual agonist |
|
98
|
248
|
2pioA |
Androgen receptor lbd with small molecule |
